Literature DB >> 1668119

Role of platelet-activating factor (PAF) in superoxide production by human polymorphonuclear leukocytes.

S Takahashi1, T Yoshikawa, Y Naito, T Tanigawa, N Yoshida, M Kondo.   

Abstract

The effect of platelet-activating factor (PAF) in superoxide production by human polymorphonuclear leukocytes (PMN) was studied. Cypridina luciferin analog (CLA) dependent chemiluminescence was used to detect superoxide anion radicals. PAF induced superoxide generation in human PMN in a dose-dependent manner. Preincubation with a small amount of PAF (5 x 10(-9) M) enhanced PMN superoxide release induced by various stimuli, such as phorbol myristate acetate (PMA), opsonized zymosan (OZ), calcium ionophore (A23187) and N-formyl-methionyl-leucyl-phenylalanine (FMLP). The PAF antagonist, CV-6209, inhibited superoxide production induced by PAF, but not that induced by other stimuli. These findings would indicate that PAF may play an important role at inflammatory reaction sites and that CV-6209 may inhibit excessive inflammatory reaction.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1668119     DOI： 10.1007/bf02536537

Source DB:  PubMed          Journal:  Lipids        ISSN： 0024-4201            Impact factor:   1.880


  16 in total

1.  Activation of NADPH oxidase in human neutrophils. Synergism between fMLP and the neutrophil products PAF and LTB4.

Authors:  B Dewald; M Baggiolini
Journal:  Biochem Biophys Res Commun       Date:  1985-04-16       Impact factor: 3.575

Review 2.  Perspectives in platelet-activating factor research.

Authors:  P Braquet; L Touqui; T Y Shen; B B Vargaftig
Journal:  Pharmacol Rev       Date:  1987-06       Impact factor: 25.468

3.  Mast cell and neutrophil interactions: a role for superoxide anion and histamine.

Authors:  R Fantozzi; S Brunelleschi; L Giuliattini; P Blandina; E Masini; G Cavallo; P F Mannaioni
Journal:  Agents Actions       Date:  1985-04

Review 4.  Molecular pathobiology of acetyl glyceryl ether phosphorylcholine: evidence for the structural and functional identity with platelet-activating factor.

Authors:  R N Pinckard; L M McManus; C A Demopoulos; M Halonen; P O Clark; J O Shaw; W T Kniker; D J Hanahan
Journal:  J Reticuloendothel Soc       Date:  1980-12

5.  Chemiluminescence probe with Cypridina luciferin analog, 2-methyl-6-phenyl-3,7-dihydroimidazo[1,2-a]pyrazin-3-one, for estimating the ability of human granulocytes to generate O2-.

Authors:  M Nakano; K Sugioka; Y Ushijima; T Goto
Journal:  Anal Biochem       Date:  1986-12       Impact factor: 3.365

6.  A chemiluminescent probe with a Cypridina luciferin analog, 2-methyl-6-phenyl-3,7-dihydroimidazo[1,2-a]pyrazin-3-one, specific and sensitive for O2- production in phagocytizing macrophages.

Authors:  K Sugioka; M Nakano; S Kurashige; Y Akuzawa; T Goto
Journal:  FEBS Lett       Date:  1986-03-03       Impact factor: 4.124

7.  Modulation of neutrophil oxidative responses to soluble stimuli by platelet-activating factor.

Authors:  J C Gay; J K Beckman; K A Zaboy; J N Lukens
Journal:  Blood       Date:  1986-04       Impact factor: 22.113

8.  CV-6209, a highly potent antagonist of platelet activating factor in vitro and in vivo.

Authors:  Z Terashita; Y Imura; M Takatani; S Tsushima; K Nishikawa
Journal:  J Pharmacol Exp Ther       Date:  1987-07       Impact factor: 4.030

9.  Specific binding by human polymorphonuclear leucocytes of the immunological mediator 1-O-hexadecyl/octadecyl-2-acetyl-sn-glycero-3-phosphorylcholine.

Authors:  F H Valone; E J Goetzl
Journal:  Immunology       Date:  1983-01       Impact factor: 7.397

10.  Biosynthesis of 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine (platelet-activating factor) from 1-alkyl-2-acyl-sn-glycero-3-phosphocholine by rat alveolar macrophages. Phospholipase A2 and acetyltransferase activities during phagocytosis and ionophore stimulation.

Authors:  D H Albert; F Snyder
Journal:  J Biol Chem       Date:  1983-01-10       Impact factor: 5.157
View more
  6 in total

1.  Activation of mouse protease-activated receptor-2 induces lymphocyte adhesion and generation of reactive oxygen species.

Authors:  S Y Lim; G M Tennant; S Kennedy; C L Wainwright; K A Kane
Journal:  Br J Pharmacol       Date:  2006-09-18       Impact factor: 8.739

2.  Therapeutic effects of intranasal tocotrienol-rich fraction on rhinitis symptoms in platelet-activating factor induced allergic rhinitis.

Authors:  Cheryl Wei Ling Teo; Stephanie Jia Ying Png; Yee Wei Ung; Wei Ney Yap
Journal:  Allergy Asthma Clin Immunol       Date:  2022-06-13       Impact factor: 3.373

3.  Superoxide production from human polymorphonuclear leukocytes by human mannan-binding protein (MBP).

Authors:  Kazuhide Uemura; Harumi Yamamoto; Tomoaki Nakagawa; Kishiko Nakamura; Nobuko Kawasaki; Shogo Oka; Bruce Yong Ma; Toshisuke Kawasaki
Journal:  Glycoconj J       Date:  2004       Impact factor: 2.916

4.  Effects of a platelet-activating factor antagonist, CV-6209, on gastric mucosal lesions induced by ischemia-reperfusion.

Authors:  T Yoshikawa; S Takahashi; Y Naito; S Ueda; T Tanigawa; N Yoshida; M Kondo
Journal:  Lipids       Date:  1992-12       Impact factor: 1.880

Review 5.  Cardiotoxicity during invasive pneumococcal disease.

Authors:  Armand O Brown; Elizabeth R C Millett; Jennifer K Quint; Carlos J Orihuela
Journal:  Am J Respir Crit Care Med       Date:  2015-04-01       Impact factor: 21.405

Review 6.  Forty Years Since the Structural Elucidation of Platelet-Activating Factor (PAF): Historical, Current, and Future Research Perspectives.

Authors:  Ronan Lordan; Alexandros Tsoupras; Ioannis Zabetakis; Constantinos A Demopoulos
Journal:  Molecules       Date:  2019-12-03       Impact factor: 4.411
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.